Amedisys Inc (AMED) Drops 7.49% on January 13

Equities Staff  |

Amedisys Inc (AMED) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 7.49% to $36.17, a loss of $-2.93 per share. Starting at an opening price of $38.97 a share, the stock traded between $35.93 and $39.32 over the course of the trading day. Volume was 237,913 shares over 2,145 trades, against an average daily volume of 338,517 shares and a total float of 33.69 million.

The losses send Amedisys Inc down to a market cap of $1.22 billion. In the last year, Amedisys Inc has traded between $48.34 and $24.81, and its 50-day SMA is currently $40.59 and 200-day SMA is $37.74.

Amedisys Inc is a provider of low-cost home health services to the chronic, co-morbid, aging American population. The Company's operations involve servicing patients through its two reportable business segments: home health and hospice.

Amedisys Inc is based out of Baton Rouge, LA and has some 13,200 employees. Its CEO is Paul B. Kusserow.

For a complete fundamental analysis analysis of Amedisys Inc, check out’s Stock Valuation Analysis report for AMED. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Crypto World in Review: Taking in the Good with the Bad

A lot happened in the cryptocurrency industry this week.

Emerging Growth

The Green Organic Dutchman Holdings Ltd.

The Green Organic Dutchman Holdings Ltd through its subsidiary operates as a cannabinoid-based research and development company in Canada.